Biochain Institute, Inc

biochain.com

BioChain is a leading technology and product provider for diagnostics and life science research community, in the fields of genomics, proteomics, drug discovery and clinical diagnosis. We are proud to be part of the biomedical community that is significantly improving people's lives.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

ATUM ANNOUNCES LICENSING DEAL WITH CODIAK FOR LEAP-IN TRANSPOSASE TECHNOLOGY

ATUM and Codiak | January 25, 2023

news image

On January 24, 2023, ATUM, a global leader in bioengineering solutions, announced that it has signed a comprehensive licensing agreement with Codiak BioSciences, a clinical-stage biopharmaceutical company, for the Leap-In Transposase® technology. ATUM will grant Codiak access to its Leap-In Transposase® technology in order to create mammalian cells expressing exosomes engineered to deliver therapeutic payloads under the conditions of the agreement. The Leap-In technology...

Read More

OBSIDIAN THERAPEUTICS ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN OF CYTODRIVE™ CELL THERAPY CANDIDATE

Obsidian Therapeutics | September 16, 2020

news image

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...

Read More

Cell and Gene Therapy

KANEKA EUROGENTEC ANNOUNCES THE SUCCESSFUL PRODUCTION OF 25G OF MRNA IN ONE BATCH

Kaneka Eurogentec | February 23, 2022

news image

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of mate...

Read More

Industrial Impact

ANTHEIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ACCELERATE PRODUCTION OF ESSENTIAL MEDICINES USING SYNTHETIC BIOLOGY

Antheia | August 13, 2021

news image

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...

Read More
news image

MedTech, Industrial Impact

ATUM ANNOUNCES LICENSING DEAL WITH CODIAK FOR LEAP-IN TRANSPOSASE TECHNOLOGY

ATUM and Codiak | January 25, 2023

On January 24, 2023, ATUM, a global leader in bioengineering solutions, announced that it has signed a comprehensive licensing agreement with Codiak BioSciences, a clinical-stage biopharmaceutical company, for the Leap-In Transposase® technology. ATUM will grant Codiak access to its Leap-In Transposase® technology in order to create mammalian cells expressing exosomes engineered to deliver therapeutic payloads under the conditions of the agreement. The Leap-In technology...

Read More
news image

OBSIDIAN THERAPEUTICS ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN OF CYTODRIVE™ CELL THERAPY CANDIDATE

Obsidian Therapeutics | September 16, 2020

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...

Read More
news image

Cell and Gene Therapy

KANEKA EUROGENTEC ANNOUNCES THE SUCCESSFUL PRODUCTION OF 25G OF MRNA IN ONE BATCH

Kaneka Eurogentec | February 23, 2022

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of mate...

Read More
news image

Industrial Impact

ANTHEIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ACCELERATE PRODUCTION OF ESSENTIAL MEDICINES USING SYNTHETIC BIOLOGY

Antheia | August 13, 2021

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us